Literature DB >> 19602286

Genome wide analysis of human genes transcriptionally and post-transcriptionally regulated by the HTLV-I protein p30.

John M Taylor1, Sofiane Ghorbel, Christophe Nicot.   

Abstract

BACKGROUND: Human T-cell leukemia virus type 1 (HTLV-I) is a human retrovirus that is etiologically linked to adult T-cell leukemia (ATL), an aggressive and fatal lymphoproliferative disease. The viral transactivator, Tax, is thought to play an important role during the initial stages of CD4+ T-cell immortalization by HTLV-1. Tax has been shown to activate transcription through CREB/ATF and NF-KB, and to alter numerous signaling pathways. These pleiotropic effects of Tax modify the expression of a wide array of cellular genes. Another viral protein encoded by HTLV-I, p30, has been shown to affect virus replication at the transcriptional and posttranscriptional levels. Little is currently known regarding the effect of p30 on the expression and nuclear export of cellular host mRNA transcripts. Identification of these RNA may reveal new targets and increase our understanding of HTLV-I pathogenesis. In this study, using primary peripheral blood mononuclear cells, we report a genome wide analysis of human genes transcriptionally and post-transcriptionally regulated by the HTLV-I protein p30.
RESULTS: Using microarray analysis, we analyzed total and cytoplasmic cellular mRNA transcript levels isolated from PBMCs to assess the effect of p30 on cellular RNA transcript expression and their nuclear export. We report p30-dependent transcription resulting in the 2.5 fold up-regulation of 15 genes and the down-regulation of 65 human genes. We further tested nuclear export of cellular mRNA and found that p30 expression also resulted in a 2.5 fold post-transcriptional down-regulation of 90 genes and the up-regulation of 33 genes.
CONCLUSION: Overall, our study describes that expression of the HTLV-I protein p30 both positively and negatively alters the expression of cellular transcripts. Our study identifies for the first time the cellular genes for which nuclear export is affected by p30. These results suggest that p30 may possess a more global function with respect to mRNA transcription and the nuclear shuttling of cellular mRNA transcripts. In addition, these alterations in gene expression may play a role in cell transformation and the onset of leukemia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19602286      PMCID: PMC2723137          DOI: 10.1186/1471-2164-10-311

Source DB:  PubMed          Journal:  BMC Genomics        ISSN: 1471-2164            Impact factor:   3.969


Background

Human T-cell leukemia virus type 1 (HTLV-I) was identified in 1980 as the first oncogenic human retrovirus. Infection is associated with adult T-cell leukemia (ATL) as well as other pathological disorders such as tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM) [1-3]. It is estimated that 25 million people worldwide are infected with HTLV-I. HTLV-I is endemic in Japan, the Caribbean, South America and Central Africa. The majority of carriers will remain asymptomatic throughout their entire lives, and data from Japan has estimated that approximately 6.6% of infected males and 2.1% of infected females will ultimately develop ATL during their lifespan [4]. HTLV-I is transmitted vertically from mother to child prior to birth or through contaminated blood products. Intriguingly, individuals infected with HTLV-1 later in life rarely present with ATL, suggesting that infection during infancy is an important factor for the development of ATL. HTLV-I is a relatively small virus with a genome only 9 kb in size that encodes for the classic retroviral structural proteins gag, pol, and env. Downstream of the env gene lies a unique region, named pX, which encodes for a number of non-structural proteins involved in virus gene expression and cell transformation, including Tax, Rex, p30, p12, p13, and HBZ. Replication of HTLV-I is dependent on the expression of the viral transactivating protein, Tax, which recruits CREB, CBP/p300 and PCAF, to activate viral gene transcription from the viral LTR [5-11]. As Tax has been implicated in the activation of a number of cell survival pathways, it is believed to be primarily responsible for facilitating cell transformation and the onset of leukemia. Tax, however, is highly immunogenic and cells expressing high amounts of Tax are readily detected and cleared by the human immune system. As a result, cells that express low amounts of Tax are preferentially selected in vivo; in fact, ATL cells from leukemic patients do not express detectable viral proteins. This selective mechanism is apparent as patients who develop ATL exhibit a clonal pattern of provirus integration and T-cell receptor rearrangement, indicating that ATL arises from a single infected progenitor cell. Other HTLV-I non-structural proteins appear to regulate various steps of virus gene expression, often through unique mechanisms. Rex is an RNA binding protein that binds to an RNA responsive element located at the 3' terminus of all viral mRNA molecules to facilitate RNA export to the cytoplasm [12-14]. In contrast to Tax and Rex which positively regulate virus gene expression, two other viral proteins have been shown to negatively regulate gene expression. HBZ, the HTLV basic leucine zipper protein, is an anti-sense-encoded protein that interferes with Tax-mediated viral gene expression [15,16]. Another intriguing viral protein, p30, is a post-transcriptional repressor of gene expression [17,18]. Specifically, p30 expression inhibits the export of the tax/rex mRNA message from the nucleus [17]. Unlike Rex, p30 does not shuttle between the nucleus and the cytoplasm and is predominantly localized to the nucleus/nucleolus, consistent with a nuclear RNA retention mechanism and function [19]. p30 interacts with Rex, and this interaction is enhanced in the presence of viral RNA, suggesting that p30 may function by binding Rex in complex with viral RNA, thereby inhibiting Rex-dependent RNA export [20]. It is not known, however, whether this interaction is required for the ability of p30 to inhibit Tax mRNA export from the nucleus. Recently, it has been shown that p30 expression also influences the cell cycle and TLR signalling [21,22]. A separate gene profile experiment suggested that p30 was able to specifically down-regulate a variety of cellular genes involved in apoptosis, cell cycle, and transcription [23]. Whether these effects are required for HTLV-I infectivity or cell transformation remains to be seen, although studies have shown that p30 expression is required for efficient virus replication and persistence in vivo [24,25]. While some information is known regarding the effects of p30 on gene transcription, the effects of p30 on cellular mRNA nuclear export have not been investigated. Using differential gene microarray analysis on total and cytoplasmic RNA extracts from peripheral blood mononuclear cells expressing p30 in comparison with mock-transduced cells, we assessed the relative abundance of cellular transcripts regulated at both the transcriptional and post transcriptional level. We found that p30 alters the expression and nucleo-cytoplasmic localization of a number of cellular transcripts involved in RNA processing, cell signalling, metabolism, and cell division. These results will help pave the way for future studies aimed at understanding the role of these cellular RNA in HTLV-I pathogenesis.

Results

p30 transcriptionally regulates the expression level of various cellular mRNAs

To analyze the transcriptional effects of p30 on global gene expression, we isolated RNA from total RNA pools following p30 expression in PBMCs using a lentiviral system. Cells were co-transfected with a packaging vector pDNL6, VSV-G to pseudotype lentiviral particles, and either empty vector pHR'CMV, or pHR'CMV:myc-p30. To ensure equivalent virus production from cells transfected with either pHR'CMV or pHR'CMV:myc-p30, we assessed the amount of lentiviral particles released into the supernatant by analyzing supernatants for HIV p24 Gag, which is a structural protein packaged as part of the lentiviral particle. Cell supernatants following transfection were harvested, lysed in SDS sample buffer and separated by SDS-PAGE. Western blotting with anti-p24 showed an equivalent amount of p24 in the supernatants of cells transfected with either the control plasmid pHR'CMV or pHR'CMV:myc-p30 (Figure 1A). We also assessed the expression of p30 by staining lentivirus-infected cells with anti-myc to detect p30 by immunofluorescence. As expected, nucleolar p30 was observed, indicating that p30 was expressed following infection of co-cultured cells (Figure 1B). To determine the percentage of cells infected using our lentiviral packaging and infection system, we co-transfected cells with pHR'CMV:GFP, which expresses GFP. Following lentiviral infection, greater than 85% of cells expressed GFP, indicating that our lentiviral packaging system is highly effective (Figure 1C).
Figure 1

Production of infectious lentiviral particles from transfected 293 T cells. A) 293 T cells were mock transfected, or transfected with pDNL6, pVSV-G, and either pHR'CMV or pHR'CMV:myc-p30, and supernatants were western blotted for HIV p24 Gag expression. B) Lymphocytes co-cultured with 293 T producer cells transfected with either pHR'CMV or pHR'CMV:myc-p30 were harvested, fixed and stained with anti-myc (9E10) and anti-mouse-Alexa488, and visualized by immunofluorescence. C) Lymphocytes co-cultured with 293 T cells transfected with either pHR'CMV or pHR'CMV:GFP were fixed and analyzed for GFP expression by flow cytometry. D) Cytosolic or nuclear protein fractions were isolated following cytoplasmic RNA extraction, and were analyzed by western blotting with either anti-cyclin A or anti-Bax to assess nuclear and cytoplasmic fraction purity, respectively.

Production of infectious lentiviral particles from transfected 293 T cells. A) 293 T cells were mock transfected, or transfected with pDNL6, pVSV-G, and either pHR'CMV or pHR'CMV:myc-p30, and supernatants were western blotted for HIV p24 Gag expression. B) Lymphocytes co-cultured with 293 T producer cells transfected with either pHR'CMV or pHR'CMV:myc-p30 were harvested, fixed and stained with anti-myc (9E10) and anti-mouse-Alexa488, and visualized by immunofluorescence. C) Lymphocytes co-cultured with 293 T cells transfected with either pHR'CMV or pHR'CMV:GFP were fixed and analyzed for GFP expression by flow cytometry. D) Cytosolic or nuclear protein fractions were isolated following cytoplasmic RNA extraction, and were analyzed by western blotting with either anti-cyclin A or anti-Bax to assess nuclear and cytoplasmic fraction purity, respectively. To examine RNA transcript levels in PBMCs in the presence and absence of p30, lentivirus-producing 293 T cells were co-cultured with peripheral blood mononuclear cells for 48 hours, total RNA was isolated and RNA samples were subjected to microarray analysis. Following microarray analysis, data sets were analyzed using the following steps: transcripts significantly present in the total RNA fraction from cells transduced with pHR'CMV lacking p30 were first selected. This data set was then sorted based on a decrease in transcript abundance following expression of p30. Sixty-five probes exhibited a decrease of greater than 2.5 fold and were deemed to be down-regulated in the presence of p30 (Table 1), and an additional 678 were down-regulated more than 1.5 fold (see Additional file 1). These genes were found to belong to several categories, such as cell signalling, transcription/translation, cell cycle, and metabolism.
Table 1

Genes down-regulated in the total RNA fraction in the presence of HTLV-I p30

Probe IDGene DescriptionGeneFold Change
Transcription/Translation/RNA Processing
1554468_s_atMitochondrial Ribosomal Protein L38FBF10.11
217340_atRibosomal Protein L21RPL210.16
231658_x_atSimilar to Ribosomal Protein L36LOC1272950.19
243560_atHeat Shock Transcription Factor 1HSF10.24
216282_x_atPolymerase (RNA) II (DNA Directed) Polypeptide C, 33 kdaPOLR2C0.25
236522_atNuclear Factor I/ANFIA0.27
1553181_atDEAD (Asp-Glu-Ala-Asp) Box Polypeptide 31DDX310.27
216117_atExosome Component 2EXOSC20.32
208345_s_atPou Domain, Class 3, Transcription Factor 1POU3F10.37
1552499_a_atZinc Finger Protein 31 (Kox 29)ZSCAN200.38
Metabolism
1569631_atNicotinamide Nucleotide Adenylyltransferase 1NMNAT10.05
217203_atGlutamate-Ammonia Ligase (Glutamine Synthetase)GLUL0.09
226209_atNADH Dehydrogenase (Ubiquinone) Flavoprotein 3, 10 kdaNDUFV30.16
239333_x_atGlutathione S-Transferase Subunit 13 HomologGSTK10.31
226947_atGlucuronidase, Beta-Like 2GUSBL20.34
213935_atAbhydrolase Domain Containing 5ABHD50.35
238724_at2,3-Bisphosphoglycerate MutaseBPGM0.37
213582_atATPase, Class VI, Type 11aATP11A0.38
236018_atAdenosine Deaminase-LikeADAL0.40
Signal Transduction
1555340_x_atRap1a, Member Of Ras Oncogene FamilyRAP1A0.00
218711_s_atSerum Deprivation Response (Phosphatidylserine Binding Protein)SDPR0.05
210374_x_atProstaglandin E Receptor 3 (Subtype Ep3)PTGER30.12
216979_atNuclear Receptor Subfamily 4, Group A, Member 3NR4A30.13
242875_atPresenilin 1 (Alzheimer Disease 3)PSEN10.13
204936_atMitogen-Activated Protein Kinase Kinase Kinase Kinase 2MAP4K20.25
211471_s_atRab36, Member Ras Oncogene FamilyRAB360.28
215134_atPhosphatidylinositol 4-Kinase Type IiPI4K2A0.33
219738_s_atProtocadherin 9PCDH90.35
239202_atRab3b, Member Ras Oncogene FamilyRAB3B0.36
205280_atGlycine Receptor, BetaGLRB0.37
209101_atConnective Tissue Growth FactorCTGF0.37
Cell Division/Cell Cycle
227578_atThymopoietinTMPO0.15
219831_atCyclin-Dependent Kinase-Like 3CDKL30.29
Cytoskeleton
239067_s_atPannexin 2PANX20.16
206117_atTropomyosin 1 (Alpha)TPM10.31
205328_atClaudin 10CLDN100.33
Transport
216504_s_atSolute Carrier Family 39 (Zinc Transporter), Member 8SLC39A80.11
242554_atTwo Pore Segment Channel 2TPCN20.40
Apoptosis
202730_s_atProgrammed Cell Death 4 (Neoplastic Transformation Inhibitor)PDCD40.34
211603_s_atEts Variant Gene 4 (E1A Enhancer Binding Protein, E1af)ETV40.34
244035_atB-Cell Cll/Lymphoma 2BCL20.36
Ubiquitin
241900_atSmad Specific E3 Ubiquitin Protein Ligase 2SMURF20.20
243216_x_atUbiquitin Specific Peptidase 40USP400.38
Other/Unknown
233351_atDNAI (Hsp40) Homolog, Subfamily C, Member 3DNAJC30.08
243221_atFamily With Sequence Similarity 20, Member AFAM20A0.08
236378_atCalcium And Integrin Binding Family Member 4CIB40.09
222109_atGuanine Nucleotide Binding Protein-Like 3 (Nucleolar)-LikeGNL3L0.09
243989_atKu-Mel-3 ProteinKU-MEL-30.13
221225_atDephospho-Coa Kinase Domain ContainingDCAKD0.13
229678_atMale-Enhanced Antigen 1MEA10.15
1552430_atWD Repeat Domain 17WDR170.24
211113_s_atATP-Binding Cassette, Sub-Family G (White), Member 1ABCG10.28
207408_atSolute Carrier Family 22 (Organic Cation Transporter), Member 14SLC22A140.30
233532_x_atIntraflagellar Transport 52 Homolog (Chlamydomonas)IFT520.34
214181_x_atLeukocyte-Specific Transcript 1LST10.35
203404_atArmadillo Repeat Containing, X-Linked 2ARMCX20.36
203765_atGrancalcin, Ef-Hand Calcium Binding ProteinGCA0.36
1555046_atFSH Primary Response (Lrpr1 Homolog, Rat) 1CENPI0.37
235991_atCUB Domain Containing Protein 2CDCP20.37
1554112_a_atUnc-51-Like Kinase 2 (C. Elegans)ULK20.37
235349_atFamily With Sequence Similarity 82, Member AFAM82A0.38
206928_atZinc Finger Protein 124 (Hzf-16)ZNF1240.39
236943_atLymphocyte Antigen 86LY860.39
242996_atMitochondrial Translational Release Factor 1MTRF10.40
Genes down-regulated in the total RNA fraction in the presence of HTLV-I p30 Among the genes down-regulated by p30 was the gene encoding anti-apoptotic Bcl-2, which is noteworthy since HTLV-1-infected cells are highly resistant to apoptosis. Bcl-2 levels, however, are not known to be elevated in HTLV-infected cells, as other anti-apoptotic proteins appear to be involved in protecting cells from apoptosis [26-28]. Another apoptosis-related gene that was down-regulated, programmed cell death-4 (PDCD4) [29], inhibits protein synthesis by suppression of translation initiation by targeting eIF-4A. In addition, loss of PDCD4 expression in human lung cancer cells has been shown to correlate with tumor progression and poor prognosis[30]. We also found that p30 down-regulates expression of Presenilin 1, a critical component of the gamma-secretase complex, which has been documented to be involved in Notch signalling [31]. Decreased expression of Presenilin 1 is associated with resistance of acute T-cell lymphoblastic leukemia (ALL) to gamma-secretase inhibitors (GSI). We have previously reported that p30 nucleolar retention is in part due to its association with the 60S ribosomal large subunit component L23A. The present study also reveals that expression of several ribosomal proteins is reduced upon p30 expression, including mitochondrial ribosomal protein L38, similar to ribosomal protein L36, and ribosomal protein L21. Rab guanine nucleotide exchange factor (GEF) and the binding partner of phosphatidyl inositol 4-kinase (PI4K) were both down-regulated by p30. Although there is no information known on HTLV-I and PI4K, HTLV infected cells have constitutive activation of PI3K [32,33]. We also observed a decrease in the expression of a number of zinc finger proteins, which are also commonly down-regulated in ATL samples [34]. We next assessed whether p30 expression resulted in the transcriptional up-regulation of any cellular transcripts. Data sets from the above samples were instead selected based on the presence of a particular transcript in the total RNA of p30-expressing cells. This data was then sorted based on an increase in transcript abundance following p30 expression as compared to samples transduced with the pHR'CMV lentivirus alone. Those probes exhibiting greater than a 2.5 fold change in abundance in the presence of p30 were deemed to be up-regulated. Interestingly, only 15 genes were up-regulated, with the largest group of genes being those involved in transcription/translation and RNA processing (Table 2). One of these genes, FOXC2, has been implicated in angiogenesis and cell migration [35]. While very few genes were seen to be up-regulated more than 2.5 fold, close to 500 genes were up-regulated between 1.5 and 2.5 fold (see Additional file 2). Interestingly, several of these genes identified are also known to be up-regulated in acute ATL, including a 90 kDa heat-shock protein, RNA polymerase II (DNA directed), regulator of G-protein signalling, [34], and general transcription factor IIH [36]. Of note, RAG-1 is up-regulated in our p30 extracts, but is conversely seen down-regulated in Tax microarray analysis [37], while Bcl-3, up-regulated in our screen (Table 2), is also up-regulated by Tax [37].
Table 2

Genes up-regulated in the total RNA fraction in the presence of HTLV-I p30

Probe IDGene DescriptionGeneFold Change
Transcription/Translation/RNA Processing
224442_ATPHD Finger Protein 6PHF63.2
219730_ATMediator Of RNA Polymerase II Transcription, Subunit 18 Homolog (Yeast)MED182.7
1560981_A_ATPeroxisome Proliferative Activated Receptor, AlphaPPARA2.6
239058_ATForkhead Box C2 (Mfh-1, Mesenchyme Forkhead 1)FOXC22.6
Metabolism
210050_ATTriosephosphate Isomerase 1TPI13.6
224042_ATUreidopropionase, BetaUPB12.6
Transport
243166_ATSolute Carrier Family 30 (Zinc Transporter), Member 5SLC30A53.0
Cell Adhesion
227209_ATContactin 1CNTN12.5
Ubiquitin/Protein Degradation
1569706_ATMyb-Like, Swirm And Mpn Domains 1MYSM12.9
203758_ATCathepsin OCTSO2.6
Other/Unknown
228493_ATA Kinase (Prka) Anchor Protein 14AKAP144.3
1559048_ATBah Domain And Coiled-Coil Containing 1BAHCC12.6
226489_ATTransmembrane And Coiled-Coil Domain Family 3TMCC32.6
1554237_ATSerologically Defined Colon Cancer Antigen 8SDCCAG82.5
227546_X_ATAurora Kinase A Interacting Protein 1AURKAIP12.5
Genes up-regulated in the total RNA fraction in the presence of HTLV-I p30

p30 post-transcriptionally regulates the levels of certain cellular mRNA transcripts

It has been demonstrated that p30 specifically inhibits the export of tax/rex mRNA molecules from the nucleus by an unknown mechanism [17]. Although tax/rex mRNA is the only known transcript which is retained in the nucleus by p30, we hypothesized that other cellular transcripts might also be subject to this virus-mediated RNA retention mechanism. To investigate whether the export of any cellular RNA transcripts from the nucleus to the cytoplasm was inhibited by p30, we isolated RNA from the cytoplasmic fraction of cells in parallel with our total RNA extractions described above. To ascertain the relative purity of cytoplasmic fractions, proteins were isolated following RNA extraction and analyzed by western blotting for known nuclear and cytoplasmic proteins, Cyclin A and Bax, respectively [38,39]. The cytoplasmic fraction was relatively free of cyclin A, while the nuclear fraction was correspondingly free of cytoplasmic Bax protein, as expected (Figure 1D). Extracted RNA samples were then subjected to microarray analysis. To identify those transcripts that p30 might inhibit the export of, we first selected transcripts that were present in equal abundance in total RNA fractions from cells either plus or minus p30. The data were then re-sorted based on the relative decrease in abundance of transcripts in the cytoplasmic fraction in the presence of p30. By ensuring that transcripts were present in the total RNA fraction in both the presence and absence of p30, any difference seen in cytoplasmic abundance of a particular transcript would not be the result of a general inhibition of transcription by p30. This parallels the repression of Tax mRNA export, where Tax mRNA is decreased in cytoplasmic RNA fractions in the presence of p30, but total Tax mRNA levels are unchanged [17]. In our screen, 90 transcripts were decreased by more than 2.5 fold (Table 3), and another 650 transcripts showed a decreased cytoplasmic abundance of more than 1.5 fold in the presence of p30 (see Additional file 3). Classes of transcripts exhibiting lower abundance in the cytoplasm in the presence of p30 include genes involved in transcription/translation, cell signalling, the cytoskeleton, DNA repair and replication, and metabolism.
Table 3

Genes down-regulated in the cytoplasm in the presence of HTLV-I p30

Probe IDGene DescriptionGeneFold Change
Transcription/Translation/RNA Processing
209060_X_ATNuclear Receptor Coactivator 3NCOA30.11
242113_ATA Kinase (Prka) Anchor Protein 8-LikeAKAP8L0.11
228711_ATZinc Finger Protein 37a (Kox 21)ZNF37A0.14
238185_ATRNA Binding Motif, Single Stranded Interacting Protein 1RBMS10.20
223409_ATForkhead Box K2FOXK20.23
1557813_ATSingle-Stranded DNA Binding Protein 2SSBP20.29
213837_ATLethal (3) Malignant Brain Tumor L(3)Mbt Protein (Drosophila) HomologL3MBTL0.31
240482_ATHistone Deacetylase 3HDAC30.32
203674_ATHelicase With Zinc FingerHELZ0.37
242407_ATArginine-Glutamic Acid Dipeptide (Re) RepeatsRERE0.38
212720_ATPoly(A) Polymerase AlphaPAPOLA0.38
1562741_ATUbx Domain Containing 2UBXD20.39
213756_S_ATHeat Shock Transcription Factor 1HSF10.40
Metabolism
213935_ATAbhydrolase Domain Containing 5ABHD50.04
237849_ATMannosidase, Alpha, Class 1a, Member 1MAN1A10.17
208917_X_ATNAD KinaseNADK0.24
1570165_ATCarbohydrate (Chondroitin 4) Sulfotransferase 11CHST110.33
238114_ATProtein-L-Isoaspartate (D-Aspartate) O-Methyltransferase Domain Containing 1PCMTD10.34
236742_ATADP-Ribosylation Factor Guanine Nucleotide-Exchange Factor 1(Brefeldin A-Inhibited)ARFGEF10.35
210963_S_ATGlycogenin 2GYG20.36
223142_S_ATUridine-Cytidine Kinase 1UCK10.37
243501_ATATP Synthase, H+ Transporting, Mitochondrial F0 Complex, Subunit B1ATP5F10.37
207904_S_ATLeucyl/Cystinyl AminopeptidaseLNPEP0.38
203180_ATAldehyde Dehydrogenase 1 Family, Member A3ALDH1A30.40
Cell Signaling/Immune System
234628_ATRab28, Member Ras Oncogene FamilyRAB280.11
201295_S_ATWD Repeat And Socs Box-Containing 1WSB10.18
235213_ATInositol 1,4,5-Trisphosphate 3-Kinase BITPKB0.19
229895_S_ATNck Adaptor Protein 1NCK10.25
223674_S_ATCDC42 Small Effector 1CDC42SE10.28
205988_ATCD84 Antigen (Leukocyte Antigen)CD840.28
242946_ATCD53 AntigenCD530.30
226375_ATLemur Tyrosine Kinase 2LMTK20.32
203854_ATComplement Factor ICFI0.36
1569022_A_ATPhosphoinositide-3-Kinase, Class 2, Alpha PolypeptidePIK3C2A0.37
204813_ATMitogen-Activated Protein Kinase 10MAPK100.38
235419_ATErbb Receptor Feedback Inhibitor 1ERRFI10.39
Cell Division/DNA Replication & Repair
229548_ATUnc-84 Homolog B (C. Elegans)UNC84B0.07
1557830_ATCyclin JCCNJ0.28
Cytoskeleton
211089_S_ATNima (Never In Mitosis Gene A)-Related Kinase 3NEK30.13
243988_ATTubulin Tyrosine Ligase-Like Family, Member 5TTLL50.14
240363_ATAnkyrin 1, ErythrocyticANK10.16
217297_S_ATMyosin IXbMYO9B0.18
1565149_ATDynein, Cytoplasmic 2, Heavy Chain 1DYNC2H10.31
236437_ATLaminin, Beta 1LAMB10.34
239170_ATArp3 Actin-Related Protein 3 Homolog (Yeast)ACTR30.37
215910_S_ATFibronectin Type III Domain Containing 3aFNDC3A0.38
Transport
1553148_A_ATSorting Nexin 13SNX130.12
233420_ATNucleoporin 133 kdaNUP1330.27
207594_S_ATSynaptojanin 1SYNJ10.30
203106_S_ATVacuolar Protein Sorting 41 (Yeast)VPS410.31
212921_ATSet And Mynd Domain Containing 2SMYD20.35
1559862_ATCoatomer Protein Complex, Subunit AlphaCOPA0.37
244219_ATWilms Tumor 1 Associated ProteinWTAP0.39
Apoptosis
1562111_ATBrain And Reproductive Organ-Expressed (Tnfrsf1a Modulator)BRE0.01
241876_ATMDM4, Transformed 3T3 Cell Double Minute 4, p53 Binding ProteinMDM40.27
Other/Unknown
227425_ATRalbp1 Associated Eps Domain Containing 2REPS20.06
244571_S_ATTetratricopeptide Repeat Domain 12TTC120.08
242870_ATFamily With Sequence Similarity 80, Member BFAM80B0.10
222566_ATSuppressor Of Variegation 4–20 Homolog 1 (Drosophila)SUV420H10.10
240149_ATAmplified In Breast Cancer 1HEATR60.11
232304_ATPellino Homolog 1 (Drosophila)PELI10.13
238995_ATSulfotransferase Family, Cytosolic, 1a, Phenol-Preferring, Member 1SULT1A10.18
231437_ATSolute Carrier Family 35, Member D2SLC35D20.19
242662_ATProprotein Convertase Subtilisin/Kexin Type 6PCSK60.20
1557394_ATDiscs, Large (Drosophila) Homolog-Associated Protein 4DLGAP40.20
238011_ATPro0149 ProteinC16ORF720.20
241268_X_ATSAM Domain And HD Domain 1SAMHD10.21
222038_S_ATWD Repeat Domain 50UTP180.22
231003_ATSolute Carrier Family 35, Member B3SLC35B30.22
242268_ATCug Triplet Repeat, RNA Binding Protein 2CUGBP20.26
202516_S_ATDiscs, Large Homolog 1 (Drosophila)DLG10.26
1556839_S_ATSpectrin, Beta, Non-Erythrocytic 5SPTBN50.27
221430_S_ATRing Finger Protein 146RNF1460.28
1558941_ATZinc Finger Protein 704ZNF7040.29
211392_S_ATZinc Finger Protein 278PATZ10.29
216604_S_ATSolute Carrier Family 7 (Cationic Amino Acid Transporter, Y+ System), Member 8SLC7A80.29
240125_ATDystrobrevin, AlphaDTNA0.30
207781_S_ATZinc Finger Protein 6 (Cmpx1)ZNF7110.30
1559078_ATB-Cell Cll/Lymphoma 11a (Zinc Finger Protein)BCL11A0.31
237747_ATFamily With Sequence Similarity 107, Member BFAM107B0.32
1570165_ATCarbohydrate (Chondroitin 4) Sulfotransferase 11CHST110.33
219846_ATGon-4-Like (C.Elegans)GON4L0.36
209766_ATPeroxiredoxin 3PRDX30.37
1556538_ATAntigen P97 (Melanoma Associated) Identified By Monoclonal Antibodies 133.2 And 96.5MFI20.37
243367_ATDopamine Receptor D5 Pseudogene 2DRD5P20.37
1552678_A_ATUbiquitin Specific Peptidase 28USP280.38
236603_ATWD Repeat Domain 32WDR320.38
224703_ATWD Repeat Domain 22WDR220.39
232362_ATCoiled-Coil Domain Containing 18CCDC180.40
213748_ATTripartite Motif-Containing 66TRIM660.40
Genes down-regulated in the cytoplasm in the presence of HTLV-I p30 Of the genes we identified, those of particular interest with respect to HTLV and the onset of leukemia include MDM4, a known regulator of p53 [40], and the single-stranded nucleic acid binding protein RBMS1, which has also been linked to transcription and apoptosis [41]. We also found that histone deacetylase HDAC3 was repressed by p30. HDAC3 is known to form multi-protein complexes with the co-repressors SMRT and N-CoR and regulates the transcription of numerous genes [42,43]. In addition, HDAC3 has multiple functions that relate to HTLV-I infected cells. HDAC3 regulates the duration of NF-kB activation by deacetylation of RelA thereby promoting its interaction with inhibitory-kB (IkB) and termination of NF-kB signalling [44]. HDAC3 has also been found to deacetylate acetyltransferases PCAF and p300/CBP and inhibit their function [45,46]. Since both PCAF and p300/CBP are required for Tax-mediated viral transcription, it makes sense that p30 would block this pathway. Finally, downregulation of HDAC3 below threshold induces G2/M arrest, a phenotype previously observed in cells overexpressing p30 [21,47]. These observations warrant further studies. Our results also indicate a decreased expression of Nup133, a nucleoporin protein involved in mRNA export [48]. This is of particular interest because of our previous work demonstrating a nuclear retention of tax/rex mRNA by p30 that is currently under investigation [17]. We then re-sorted the data to examine whether any genes showed an increased abundance in the cytoplasm in the presence of p30. Intriguingly, despite the role of p30 as an inhibitor of Tax mRNA export, we observed 33 genes that showed an increased abundance of more than 2.5 fold in the cytoplasm in the presence of p30 (Table 4), and another 930 genes increased in the cytoplasm more than 1.5 fold (see Additional file 4). These probes were present in equal quantities in the total RNA fractions, indicating that their increased abundance in the cytoplasm was not due to an altered expression pattern at the transcriptional level. Of particular interest are groups of genes involved in DNA replication and repair, apoptosis, cell adhesion, and cell signalling, all of which are known classes of genes to be intimately linked with the onset of cancer. Again, none of the genes identified in our screen were previously shown to be significantly altered in ATL cells [34]. Upregulated genes include two Rab GTPases, which are believed to play a role in oncogenesis [49], and CCAR1, which is involved in gene expression and functions as a p53 coactivator [50]. Other genes observed to be increased between 1.5 and 2.5 fold include XRCC1 binding protein-1, which parallels a previous observation describing an increase in abundance of XRCC1 DNA repair gene in ATL cells [36]. We also observed granzyme B and perforin to be up-regulated in the cytoplasm of p30-expressing cells, contrasting a decrease in the expression of granzyme A in ATL cells [34]. Whether these cytotoxic molecules are involved in the pathogenesis or development of disease in HTLV-I-infected T-cells remains to be investigated.
Table 4

Genes up-regulated in the cytoplasm in the presence of HTLV-I p30

Probe IDGene DescriptionGeneFold Change
Transcription/Translation
236566_ATCell Division Cycle And Apoptosis Regulator 1CCAR12.8
230998_ATChromobox Homolog 3 (Hp1 Gamma Homolog, Drosophila)CBX32.7
236244_ATHeterogeneous Nuclear Ribonucleoprotein U (Scaffold Attachment Factor A)HNRNPU2.6
Metabolism
233445_ATBub1 Budding uninhibited by Benzimidazoles 1 Homolog (Yeast)BUB12.5
221139_S_ATCysteine Sulfinic Acid DecarboxylaseCSAD2.7
204646_ATDihydropyrimidine DehydrogenaseDPYD3.2
242235_X_ATNardilysin (N-Arginine Dibasic Convertase)NRD12.6
229465_S_ATProtein Tyrosine Phosphatase, Receptor Type, DPTPRS2.7
242905_ATPutatative 28 KDa ProteinPNO13.1
38964_R_ATWiskott-Aldrich Syndrome (Eczema-Thrombocytopenia)WAS2.6
Signal Transduction
1552312_A_ATMicrofibrillar-Associated Protein 3MFAP32.5
220500_S_ATRab, Member of Ras Oncogene Family-Like 2aRABL2A4.1
220500_S_ATRab, Member of Ras Oncogene Family-Like 2bRABL2B4.1
239031_ATSomatostatin Receptor 2SSTR22.9
Cell Division/DNA Replication
234605_ATCDC14 Cell Division Cycle 14 Homolog B (S. Cerevisiae)CDC14B3.0
1566043_ATInner Centromere Protein Antigens 135/155 kdaINCENP2.9
228670_ATTelomerase-Associated Protein 1TEP12.5
Transport
1558028_X_ATTranslocation Associated Membrane Protein 1TRAM12.7
Development
224368_S_ATNdrg Family Member 3NDRG32.5
217107_ATRibosomal Protein S4, X-LinkedRPS4X2.6
232975_ATTripartite Motif-Containing 26TRIM262.5
Apoptosis
40489_ATAtrophin 1ATN12.9
Other/Unknown
219301_S_ATContactin Associated Protein-Like 2CNTNAP22.8
230701_X_ATKinesin Family Member 9KIF92.9
241385_ATDkfzp564k112 ProteinLARP72.7
226078_ATRNA Pseudouridylate Synthase Domain Containing 1RPUSD13.6
234725_S_ATSema Domain, Immunoglobulin Domain (Ig), Transmembrane Domain (Tm) And Short Cytoplasmic Domain, (Semaphorin) 4bSEMA4B2.5
243768_ATSumo1/Sentrin Specific Peptidase 6SENP62.5
209253_ATSorbin And SH3 Domain Containing 3SORBS33.0
232493_ATSignal Peptidase Complex Subunit 1 Homolog (S. Cerevisiae)SPCS12.5
243198_ATTestis Expressed Sequence 9TEX92.8
232528_ATUbiquitin-Conjugating Enzyme E2e 3 (UBC4/5 Homolog, Yeast)UBE2E4P2.8
240155_X_ATZinc Finger Protein 493ZNF4932.5
Genes up-regulated in the cytoplasm in the presence of HTLV-I p30

Discussion

The regulation of viral and cellular transcripts is of great importance, particularly with respect to latent viruses that persist in the human host for extended periods of time. In the case of adult T-cell leukemia, leukemic cells are infected with HTLV-I and contain the proviral genome, but there is extremely little expression of viral transcripts. Despite being a non-structural protein that localizes to the nucleolus, the HTLV-I accessory protein p30 is required for efficient infection in vivo [19,24]. Recent studies by our group and others have since shown that p30 acts as a negative regulator of virus expression by inhibiting the nuclear export of tax/rex mRNA [17,18]. Additional studies have reported that p30 is a transcriptional inhibitor of the viral LTR. In addition to regulating the export of tax/rex mRNA to the cytoplasm, p30 expression modifies a number of signalling pathways such as TLR4, CREB, and GSK3β [22,51,52]. How p30 accomplishes these changes in the cell is currently unknown. p30 has, however, been documented to facilitate transcription from cellular and viral promoters in conjunction with the transcriptional coactivator p300/CBP [51]. Thus, similar to another nucleolar protein, nucleolin, p30 possesses both transcriptional and posttranscriptional activities. The combination of these effects likely decrease Tax and other viral antigen expression, possibly permitting HTLV-I infected cells to remain hidden from the immune response. In this study, we used a genome wide analysis to investigate the effect of p30 on host cell gene regulation and found a number of cellular transcripts to be increased or decreased (Tables 1, 2; see Additional files 1 and 2). These genes belonged to a variety of families, including transcriptional/translational control, cell cycle, DNA replication and repair, and cell signalling. While it is not yet known whether changes in expression of any of these genes identified here, alone or in combination, are required for cell transformation induced by HTLV-I, some have been shown to have altered expression patterns in acute ATL, such as PDCD4, 90 kDa heat-shock protein, RNA polymerase II (DNA directed), regulator of G-protein signalling, general transcription factor IIH, and Bcl-3 [34,36,37]. Considering the possibility that p30 plays a role in the onset of ATL in HTLV-I-infected individuals, some of the genes regulated by p30 may be involved in the process of cell transformation. Using a different experimental approach which relied upon long-term stable expression of p30 in Jurkat lymphocytes, it was previously shown that p30 alters the general abundance of a number of cellular genes [23]. Several of the transcripts shown previously to be down-regulated were indeed seen in our array as also being negatively regulated by p30, but the difference was less than a 2.5-fold change in expression. The differences between these reports are not surprising given the differences in the methodology and cell lines used for these two experiments. While our study used a short-term lentiviral infection and co-transduction of peripheral blood mononuclear cells, Michael et al. used a long-term lentiviral transduction of Jurkat T-lymphocytes. It is also worthwhile to consider that long-term p30 expression has been documented to induce cell cycle alterations, which may also lead to different changes in gene expression [21]. Considering the differences, both studies are beneficial to help understand the role that p30 plays in modulating gene expression. The main objective of this study was to evaluate whether any cellular genes were regulated post-transcriptionally by p30, in much the same way that p30 regulates Tax expression by preventing tax/rex mRNA export to the cytoplasm. While it is not yet known exactly how p30 inhibits the export of tax/rex mRNA, we hypothesized that p30 would alter the cytoplasmic abundance of cellular transcripts. In fact, we observed a number of cellular transcripts that showed either a decreased or increased abundance in the cytoplasm (Tables 3, 4). While none of these genes were previously identified as being regulated in ATL samples, this was to be expected since in our experimental approach the total abundance of the genes characterized in Tables 3 and 4 was unchanged and only cytoplasmic abundance was affected. So how does p30 inhibit mRNA export into the cytoplasm? It is possible that p30 somehow modulates the activity of a cellular export mechanism. If this were the case, this might explain why a variety of cellular transcripts were altered in cytoplasmic abundance, indicative of a global effect. Alternatively, p30 may bind to mRNA transcripts to prevent their association with nuclear export proteins, and cellular transcripts that are inhibited may share sequence or secondary structural similarities with the tax/rex mRNA. It has been hypothesized that p30 may function by binding to both RNA and to Rex, another HTLV-I protein that is conversely responsible for up-regulating tax/rex mRNA export from the nucleus [20]. Indeed, there is evidence to suggest that p30 does bind to RNA [17,20], and that p30 might recognize a particular RNA sequence that is present in the tax-rex message, a short 150 base pair response element present specifically at the tax/rex splice junction [17]. Whether these interactions are required for the inhibition of tax/rex mRNA export is not currently known. In the current study, Rex was not expressed, suggesting that p30 can function in the absence of Rex. As a result, it is more likely that p30 might have a broad mechanism of action that applies to a number of transcripts. On the other hand it is also possible that p30 directly or indirectly alters regulation or function of RNA export machinery. In this way p30 may actually only alter the expression or export of a few genes. The altered expression of these, in turn, might then be required for the normal expression of remaining transcripts shown to be altered in the presence of p30. Future work is required to examine the effects of p30 at the level of protein expression of candidate proteins. Another possibility explaining the function of p30 involves the binding and alteration of known cellular proteins involved in RNA modification and transport. Again, if p30 alters a known cellular mRNA trafficking pathway, it would not come as a surprise to observe so many cellular RNA transcripts as having altered expression patterns, both in total RNA samples and in cytoplasmic fractions. Following binding to RNA, p30 might then prevent the subsequent docking and function of splicing and/or mRNA export factors. Whether p30 recognizes the sequence of this region or recognizes a secondary RNA structure is not known. Indeed, such regulation has been reported for how the retroviral HTLV Rex protein and HIV Rev protein interact with their respective RNA binding sites [53,54]. While there are no sequence similarities between the Rex responsive element (RexRE) and the Rev responsive element (RRE), HIV Rev functionally interacts with both sites while Rex is specific for the RexRE. Computer prediction of secondary structures of numerous mRNA transcripts using specific software is not an easy task but warrants future study. Whether p30 interacts with RNA in a sequence-specific or secondary structure-specific manner, there may exist similarities between the tax/rex message and those transcripts down-regulated in the cytoplasm (Additional file 3), and examining these similarities will likely be the subject of future work. In addition, such an analysis may lead to the identification of an RNA binding motif in the p30 protein. If such a motif were found, it could also possibly lead to identification of therapeutic agents that could target such a binding motif in p30. By impairing the function of p30, one could hope to break latency and increase Tax expression in HTLV-infected patients, leading to the increased detection of infected cells by the immune system and the eventual clearance of infected cells from the body. This could perhaps provide an effective therapy for HTLV-I-infected individuals, thereby protecting patients from developing ATL later in life.

Conclusion

In conclusion our data demonstrate that the expression of numerous cellular genes is affected by HTLV-I p30 either at the transcriptional or at the post-transcriptional (nuclear export) level suggesting that p30 may alter normal cellular homeostasis and favour transformation.

Methods

Lentivirus Production and Transduction

The lentiviral HIV-based vector pHR'CMV containing HTLV-I p30, the CMV-driven HIV helper virus deleted for the env and nef genes(pDNL6), and the HIV long terminal repeat-vesicular stomatitis virus G (pVSV-G) envelope were described previously [17,55]. Semi-confluent 293 T cells were transfected with packaging plasmid pDNL6, pHR'CMV:myc-p30 or pHR'CMV, and pVSV-G using calcium phosphate (Invitrogen) according to the manufacturer's instructions. At 48 hours post-transfection, cells were washed thoroughly and co-cultured with freshly isolated PBMCs. Cells were allowed to co-culture for another 48 hours, and only the non-adherent PBMCs present in the supernatant were harvested, to separate them from adherent 293 T producer cells. Myc-p30 expression was evaluated by immunofluorescence. Infected suspension cells were plated onto glass coverslips by centrifugation, fixed with 4% paraformaldehyde, permeabilized with 0.5% Triton-X-100, and stained with anti-myc (9E10; Santa Cruz Biotechnology), and anti-mouse-Alexa546 secondary (Molecular Probes). Cells were co-stained with DAPI, mounted on glass slides and imaged using a Nikon Eclipse Ti-S inverted fluorescent microscope. To assess the rate of lentiviral infection, an assay using GFP in place of the myc-p30 gene was used (pHR'CMV:GFP). 293 T cells were transfected for 48 hours and co-cultured as described above, and cells were harvested after 48 hours. Cells were fixed in 4% paraformaldehyde and analyzed for GFP expression by flow cytometry using a FACScalibur (BD Biosciences). To determine the rate of virus production from mock producer cells or myc-p30 lentivirus producer cells, 293 T cell supernatants were harvested at 48 hours post transfection and analyzed by western blotting with antisera against HIV p24 (NIH AIDS Research and Reference Reagent Program).

RNA Extraction and analysis

RNA from total cell extracts was isolated using Trizol (Invitrogen) according to the manufacturer's instructions. Cytoplasmic RNA was isolated by resuspending cells in a hypotonic lysis buffer (10 mM HEPES pH7.9, 1 mM MgCl2, 0.5 mM CaCl2, 20 mM Ribosyl complex, and 1000 U/mL of RNaseOUT (Invitrogen)), and incubated in ice for 15 min. NP-40 was then added to a final concentration of 0.27% and the lysate was immediately vortexed for 30 seconds. Cells were centrifuged, the supernatant (cytosolic) fraction was harvested, and proteinase K (50 ug/ml) was added and incubated at 37°C for 30 min. RNA was extracted twice with an equal volume of chloroform, and the final supernatant was precipitated with an equal volume of isopropanol containing 300 mM sodium acetate at -20°C. RNA samples were washed twice with 70% ethanol, and the RNA pellet was resuspended in 100 ul DEPC-H2O containing RNaseOUT (Invitrogen) and ribosyl vanadayl complex (Sigma). Samples were then treated with DNase (10 U/ul) for 1 hour at 37°C, and extracted with chloroform. Extracted aqueous fractions were precipitated with an equal volume of isopropanol overnight at -20°C. RNA samples were centrifuged, RNA pellets were washed twice with 70% ethanol, and resuspended in DEPC-H2O containing RNaseOUT (Invitrogen). RNA was quantified using a spectrophotometer and then stored at -80°C. To assess the purity of cytoplasmic and nuclear RNA fractions, protein lysates from the cytoplasmic or nuclear fractions following cytoplasmic RNA extraction were analyzed by western blotting with anti-Cyclin A (H-432; Santa Cruz Biotechnology) or anti-Bax (N20; Santa Cruz Biotechnology).

Microarray Analysis

RNA samples were analyzed by microarray analysis in duplicate using an Affymetrix high-density chip, HG-U133 (Plus-2). Microarray hybridization and detection were performed as described in the Affymetrix GeneChip Expression Analysis Technical Manual. Microarray data analysis was performed according to the Affymetrix GeneChip Expression Analysis (Data Analysis Fundamentals) by the K-INBRE Bioinformatics Core (Kansas IDeA Network of Biomedical Research Excellence). Minimum information about a microarray experiment (MIAME) criteria were met [56], and the complete microarray datasets described can be found at the National Center for Biotechnology Information Gene Expression Omnibus (accession number: GSE16098). Functional annotation of transcripts was performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) [57].

Authors' contributions

SG and JMT performed the experiments. JMT analyzed the data and wrote the manuscript. CN developed the project, analyzed the data and wrote the manuscript. All authors have read and approved the final manuscript.

Additional file 1

Supplemental table 1. Genes Downregulated >1.5 Fold in Total RNA in the presence of p30. Click here for file

Additional file 2

Supplemental Table 2. Genes upregulated >1.5 Fold in Total RNA in the presence of p30. Click here for file

Additional file 3

Supplemental Table 3. Genes Downregulated >1.5 Fold in the cytoplasm in the presence of p30. Click here for file

Additional file 4

Supplemental Table 4. Genes Upregulated >1.5 Fold in the cytoplasm in the presence of p30. Click here for file
  57 in total

1.  Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells.

Authors:  Soo-Jin Jeong; Cynthia A Pise-Masison; Michael F Radonovich; Hyeon Ung Park; John N Brady
Journal:  Oncogene       Date:  2005-10-06       Impact factor: 9.867

2.  Human T-cell leukemia virus type I p30 nuclear/nucleolar retention is mediated through interactions with RNA and a constituent of the 60 S ribosomal subunit.

Authors:  Sofiane Ghorbel; Uma Sinha-Datta; Miroslav Dundr; Megan Brown; Genoveffa Franchini; Christophe Nicot
Journal:  J Biol Chem       Date:  2006-09-28       Impact factor: 5.157

3.  Inhibition of histone deacetylase 3 stimulates apoptosis induced by heat shock under acidic conditions in human maxillary cancer.

Authors:  Norihiko Narita; Shigeharu Fujieda; Masaharu Tokuriki; Noboru Takahashi; Hideaki Tsuzuki; Toshio Ohtsubo; Hideki Matsumoto
Journal:  Oncogene       Date:  2005-11-10       Impact factor: 9.867

4.  Mitochondria-independent induction of Fas-mediated apoptosis by MSSP.

Authors:  Jun Nomura; Ken-Ichi Matsumoto; Sanae M M Iguchi-Ariga; Hiroyoshi Ariga
Journal:  Oncol Rep       Date:  2005-11       Impact factor: 3.906

5.  The HTLV-I p30 interferes with TLR4 signaling and modulates the release of pro- and anti-inflammatory cytokines from human macrophages.

Authors:  Abhik Datta; Uma Sinha-Datta; Navneet Kaur Dhillon; Shilpa Buch; Christophe Nicot
Journal:  J Biol Chem       Date:  2006-06-19       Impact factor: 5.157

Review 6.  Emerging role of RAB GTPases in cancer and human disease.

Authors:  Kwai W Cheng; John P Lahad; Joseph W Gray; Gordon B Mills
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

7.  HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells.

Authors:  Yorifumi Satou; Jun-ichirou Yasunaga; Mika Yoshida; Masao Matsuoka
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-09       Impact factor: 11.205

8.  Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2.

Authors:  Serge Grégoire; Lin Xiao; Jianyun Nie; Xiaohong Zhang; Minghong Xu; Jiarong Li; Jiemin Wong; Edward Seto; Xiang-Jiao Yang
Journal:  Mol Cell Biol       Date:  2006-12-11       Impact factor: 4.272

9.  An exposed KID-like domain in human T-cell lymphotropic virus type 1 Tax is responsible for the recruitment of coactivators CBP/p300.

Authors:  R Harrod; Y Tang; C Nicot; H S Lu; A Vassilev; Y Nakatani; C Z Giam
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

10.  Histone deacetylase 3 binds to and regulates the GCMa transcription factor.

Authors:  Hsiao-Ching Chuang; Ching-Wen Chang; Geen-Dong Chang; Tso-Pang Yao; Hungwen Chen
Journal:  Nucleic Acids Res       Date:  2006-03-09       Impact factor: 16.971

View more
  19 in total

1.  Requirement of the human T-cell leukemia virus p12 and p30 products for infectivity of human dendritic cells and macaques but not rabbits.

Authors:  Valerio W Valeri; Anna Hryniewicz; Vibeke Andresen; Kathy Jones; Claudio Fenizia; Izabela Bialuk; Hye Kyung Chung; Risaku Fukumoto; Robyn Washington Parks; Maria Grazia Ferrari; Christophe Nicot; Valentina Cecchinato; Frank Ruscetti; Genoveffa Franchini
Journal:  Blood       Date:  2010-07-20       Impact factor: 22.113

2.  Human T-lymphotropic type 1 virus p30 inhibits homologous recombination and favors unfaithful DNA repair.

Authors:  Hicham H Baydoun; Joanna Pancewicz; Christophe Nicot
Journal:  Blood       Date:  2011-03-22       Impact factor: 22.113

3.  Polymorphic Nature of Human T-Cell Leukemia Virus Type 1 Particle Cores as Revealed through Characterization of a Chronically Infected Cell Line.

Authors:  Morgan E Meissner; Luiza M Mendonça; Wei Zhang; Louis M Mansky
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

4.  Acetylation of the c-MYC oncoprotein is required for cooperation with the HTLV-1 p30(II) accessory protein and the induction of oncogenic cellular transformation by p30(II)/c-MYC.

Authors:  Megan M Romeo; Bookyung Ko; Janice Kim; Rebecca Brady; Hayley C Heatley; Jeffrey He; Carolyn K Harrod; Braden Barnett; Lee Ratner; Michael D Lairmore; Ernest Martinez; Bernhard Lüscher; Craig N Robson; Marie Henriksson; Robert Harrod
Journal:  Virology       Date:  2015-01-05       Impact factor: 3.616

5.  HTLV-I p30: a versatile protein modulating virus replication and pathogenesis.

Authors:  Xue Tao Bai; Hicham Hachem Baydoun; Christophe Nicot
Journal:  Mol Aspects Med       Date:  2010-06-04

6.  Comparative host protein interactions with HTLV-1 p30 and HTLV-2 p28: insights into difference in pathobiology of human retroviruses.

Authors:  Rami Doueiri; Rajaneesh Anupam; Mamuka Kvaratskhelia; Kari B Green; Michael D Lairmore; Patrick L Green
Journal:  Retrovirology       Date:  2012-08-09       Impact factor: 4.602

Review 7.  Orf-I and orf-II-encoded proteins in HTLV-1 infection and persistence.

Authors:  Dustin Edwards; Claudio Fenizia; Heather Gold; Maria Fernanda de Castro-Amarante; Cody Buchmann; Cynthia A Pise-Masison; Genoveffa Franchini
Journal:  Viruses       Date:  2011-06-17       Impact factor: 5.048

Review 8.  Converging strategies in expression of human complex retroviruses.

Authors:  Ilaria Cavallari; Francesca Rende; Donna M D'Agostino; Vincenzo Ciminale
Journal:  Viruses       Date:  2011-08-11       Impact factor: 5.048

9.  Comparison of the Genetic Organization, Expression Strategies and Oncogenic Potential of HTLV-1 and HTLV-2.

Authors:  Francesca Rende; Ilaria Cavallari; Maria Grazia Romanelli; Erica Diani; Umberto Bertazzoni; Vincenzo Ciminale
Journal:  Leuk Res Treatment       Date:  2011-12-29

10.  Overview on HTLV-1 p12, p8, p30, p13: accomplices in persistent infection and viral pathogenesis.

Authors:  Xue Tao Bai; Christophe Nicot
Journal:  Front Microbiol       Date:  2012-12-11       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.